Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amanda J Hooper

Showing results (11-20 of 125) with videos related to

Pageof 13
Sort By:
Expert Opinion on Investigational Drugs|December 24, 2011
Anacetrapib, a cholesteryl ester transfer protein inhibitorAmanda J Hooper, John R Burnett
Expert Opinion on Investigational Drugs|October 10, 2023
MK-0616: an oral PCSK9 inhibitor for hypercholesterolemia treatmentJohn R Burnett, Amanda J Hooper
Free Radical Biology & Medicine|June 19, 2015
Vitamin E and oxidative stress in abetalipoproteinemia and familial hypobetalipoproteinemiaJohn R Burnett, Amanda J Hooper
Expert Opinion on Investigational Drugs|October 3, 2025
Emerging ANGPTL3-directed therapies for hyperlipidemia: insights from two recent phase II trialsAmanda J Hooper, Thusyanthy Parameswaran, John R Burnett
Expert Opinion on Emerging Drugs|April 19, 2026
Injectable, oral, gene-based, and vaccine-driven PCSK9-targeted therapies: emerging clinical insights shaping the future of hypercholesterolemia managementThusyanthy Parameswaran, Amanda J Hooper, John R Burnett
Expert Opinion on Investigational Drugs|January 8, 2011
Mipomersen, an antisense apolipoprotein B synthesis inhibitorDamon A Bell, Amanda J Hooper, John R Burnett
Expert Opinion on Biological Therapy|May 17, 2025
An evaluation of recaticimab for the treatment of hypercholesterolemiaXuan L Tang, Amanda J Hooper, John R Burnett
Expert Opinion on Investigational Drugs|April 3, 2026
<i>ANGPTL3</i> gene editing with CRISPR-Cas9: early trial insightsXuan L Tang, Amanda J Hooper, John R Burnett
Journal of Lipid Research|January 20, 2011
Genetic determinants of hepatic steatosis in manAmanda J Hooper, Leon A Adams, John R Burnett
Expert Opinion on Investigational Drugs|June 15, 2024
VERVE-101, a CRISPR base-editing therapy designed to permanently inactivate hepatic PCSK9 and reduce LDL-cholesterolAmanda J Hooper, Xuan L Tang, John R Burnett
Pageof 13

Showing results (11-20 of 125) with videos related to

Sort By:
Pageof 13
Expert Opinion on Investigational Drugs|December 24, 2011
Anacetrapib, a cholesteryl ester transfer protein inhibitorAmanda J Hooper, John R Burnett
Expert Opinion on Investigational Drugs|October 10, 2023
MK-0616: an oral PCSK9 inhibitor for hypercholesterolemia treatmentJohn R Burnett, Amanda J Hooper
Free Radical Biology & Medicine|June 19, 2015
Vitamin E and oxidative stress in abetalipoproteinemia and familial hypobetalipoproteinemiaJohn R Burnett, Amanda J Hooper
Expert Opinion on Investigational Drugs|October 3, 2025
Emerging ANGPTL3-directed therapies for hyperlipidemia: insights from two recent phase II trialsAmanda J Hooper, Thusyanthy Parameswaran, John R Burnett
Expert Opinion on Emerging Drugs|April 19, 2026
Injectable, oral, gene-based, and vaccine-driven PCSK9-targeted therapies: emerging clinical insights shaping the future of hypercholesterolemia managementThusyanthy Parameswaran, Amanda J Hooper, John R Burnett
Expert Opinion on Investigational Drugs|January 8, 2011
Mipomersen, an antisense apolipoprotein B synthesis inhibitorDamon A Bell, Amanda J Hooper, John R Burnett
Expert Opinion on Biological Therapy|May 17, 2025
An evaluation of recaticimab for the treatment of hypercholesterolemiaXuan L Tang, Amanda J Hooper, John R Burnett
Expert Opinion on Investigational Drugs|April 3, 2026
<i>ANGPTL3</i> gene editing with CRISPR-Cas9: early trial insightsXuan L Tang, Amanda J Hooper, John R Burnett
Journal of Lipid Research|January 20, 2011
Genetic determinants of hepatic steatosis in manAmanda J Hooper, Leon A Adams, John R Burnett
Expert Opinion on Investigational Drugs|June 15, 2024
VERVE-101, a CRISPR base-editing therapy designed to permanently inactivate hepatic PCSK9 and reduce LDL-cholesterolAmanda J Hooper, Xuan L Tang, John R Burnett
Pageof 13